Abstract
Data from 1330 human immunodeficiency virus type 1 (HIV-1)-infected patients enrolled in seven antiretroviral treatment trials were analyzed to characterize the clinical benefit of treatment-mediated reductions in plasma HIV-1 RNA levels. The risk of a new AIDS-defining event or death was reduced proportionally to the magnitude of the reduction of the HIV-1 RNA level during the first 6 months of therapy. Pretherapy HIV-1 RNA levels were prognostic independently of on-therapy levels. In addition, the reduction in risk associated with any given reduction of the level of HIV-1 RNA did not vary by pretherapy level. Having either a reduction in HIV-1 RNA level or an increase in CD4+ lymphocyte count, or both, was associated with a delay in clinical disease progression. This indicates that patient prognosis should be assessed using both HIV-1 RNA and CD4+ lymphocyte responses to therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 40-47 |
Number of pages | 8 |
Journal | Journal of Infectious Diseases |
Volume | 177 |
Issue number | 1 |
DOIs | |
State | Published - 1998 |
Funding
Financial support: NIH (AIDS Clinical Trials Group, AI-28270, AI-27670, AI-38858, AI-29164, AI-27664, AI-30731, AI-29193, AI-27659, AI-32775, and AI-32794 and AI-36214 [to University of California at San Diego Center for AIDS Research]); Research Center for AIDS and HIV Infection of the San Diego VA Medical Center; University of Alabama at Birmingham Center for AIDS Research; Birmingham VA Medical Center.
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy